- Novel antibodies identified that block the CD73 immune
checkpoint for cancer immunotherapy;
- Strengthens Innate's positioning in targeting the tumor
microenvironment.
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 -
IPH) today presented data on a research program to develop a CD73
checkpoint inhibitor antibody in oncology at the American
Association for Cancer Research (AACR) Annual Meeting 2016 in New
Orleans, Louisiana, USA. This new anti-CD73 project complements
Innate's first-in-class anti-CD39 program strengthening the
Company's positioning in targeting the tumor microenvironment.
CD73 and CD39 are two enzymes which play a major
role in promoting immunosuppression through the pathway degrading
adenosine triphosphate (ATP) into adenosine. CD73 is active on the
last step of the degradation pathway, where it is the enzyme that
actually degrades AMP[*] into adenosine.
Poster #2344 presented a panel of newly
generated antibodies that block CD73 function. They all bind with
high affinity and specificity to the CD73 enzyme, but to distinct
epitopes and display different mechanisms of inhibition, including
direct blocking of CD73 enzymatic activity or down-modulation of
CD73 membrane expression. All antibodies strongly reduce AMP
catabolism and efficiently reverse adenosine-mediated T cell
suppression in vitro. The antibodies displaying the most
interesting features were humanized and further evaluation of their
activity is ongoing.
Nicolai Wagtmann, CSO of Innate Pharma, said:
"This program adds to our innovative and diversified portfolio of
checkpoint inhibitors. We are entering the very exciting and novel
area of microenvironment checkpoint inhibition which complements
other immuno-oncology approaches. Our anti-CD73 and anti-CD39
antibodies each have potential as single-agent therapeutics and for
combination with other checkpoint blockers notably targeting T or
NK cells".
***** Reminder:
Nicolai Wagtmann, Chief Scientific Officer of
Innate Pharma, will hold a conference call to the attention
of analysts and portfolio managers to discuss the data published
and Company's innovative pipeline.
Time and dial in: Tuesday, April 19th 10:30am
Eastern Time USA: 888 504 7963 International:
+1 719 325 2452 Access code: 1890466 Webcast:
http://urlz.fr/3pxC
*****
About the anti-CD73 antibody program:
CD73 is a membrane-bound extracellular enzyme
overexpressed in several cancer types. Its expression has been
linked to poor prognosis in melanoma, colorectal, gastric, triple
negative breast cancer, and to a pro-metastatic phenotype in
prostate cancer[1].
Together with CD39, it plays a major role in
promoting immunosuppression through the pathway degrading adenosine
triphosphate (ATP) into adenosine. Within the tumor
microenvironment, ATP promotes immune cell-mediated killing of
cancer cells. In contrast, adenosine accumulation causes immune
suppression, dysregulation of immune cell infiltrates and
stimulates angiogenesis resulting in tumor spreading. CD73 is
active on the last step of the degradation pathway, where it is the
enzyme that actually degrades AMP into adenosine. CD73-blockade
promotes anti-tumor immunity by reducing adenosine accumulation.
Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and
reduce tumor metastasis in mouse tumor models, and could enhance
the efficacy of treatment with anti-PD1 or anti-CTLA4
antibodies[2].
Innate Pharma has generated a panel of new
anti-CD73 antibodies. The antibodies displaying the most
interesting features were humanized and further evaluation of their
activity is ongoing.
This program is developed within the TumAdoR
project[§] (www.tumador.eu), coordinated by Dr C. Caux
(Centre Léon Bérard and Centre de Recherche en Cancérologie, Lyon,
France), and funded under the European Community's seventh
framework Program[**].
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical
company discovering and developing first-in-class therapeutic
antibodies for the treatment of cancer and inflammatory
diseases.
Innate Pharma specializes in immuno-oncology, a
new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to
recognize and kill cancer cells.
The Company has pioneered the development of
antibodies that block inhibitory checkpoint receptors on NK cells.
Today, Innate Pharma has three first-in-class antibodies in
clinical development in immuno-oncology and a pipeline of
preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into
alliances with leaders in the biopharmaceutical industry such as
Bristol-Myers Squibb and AstraZeneca, Sanofi and Novo Nordisk
A/S.
Based in Marseille, France, Innate Pharma had
118 employees as at December 31, 2015. The company is listed on
Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Practical Information about Innate Pharma
shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website or on Innate Pharma's website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Innate Pharma |
ATCG
Press |
Laure-Hélène Mercier Director,
Investor Relations |
Marie
Puvieux (France) Mob: +33 (0)6 10 54 36 72 Jean-Medhi Grangeon
(ROW) |
Tel.: +33 (0)4 30 30 30 87 |
Mob: +33
(0)6 62 22 00 24 |
investors@innate-pharma.com |
presse@atcg-partners.com |
[*] Adenosine monophosphate
[1] Liu et al., 2012; Wu et al., 2012; Lu et
al., 2013; Loi et al., 2013; Wang et al., 2012; Yang et al.,
2013
[2] Allard et al., 2013
[§] Another poster on CD73 will be presented by
the consortium : Abstract #2338, CD39+ Treg cooperate with a
CD73-expressing TH&/Th17 subset for Adenosine-mediated
immunosuppression in human breast tumors, Dr. Caux (CLB)
[**] European Community's Seventh Framework
Program (FP7/2007-2013) under grant agreement n°602200.
IPH AACR 2016 CD73
http://hugin.info/155662/R/2004573/740208.pdf
HUG#2004573
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024